Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142).
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2012
At a glance
- Drugs Bortezomib (Primary)
- Indications Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- 22 Feb 2012 Planned number of patients changed from 25 to 28 as reported by European Clinical Trials Database.
- 28 Jul 2009 Actual end date (Nov 2007) and actual number of patients (12) added as reported by ClinicalTrials.gov.
- 28 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.